Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI

Author

Jinbo Zhao

h-index 26 View on Semantic Scholar

We have 3 of 143 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Prognostic Stratification of Adjuvant Immunotherapy After Neoadjuvant Chemoimmunotherapy and Quality Surgery in LA-ESCC.

BACKGROUND In locally advanced esophageal squamous cell carcinoma (LA-ESCC), neoadjuvant chemoimmunotherapy (NCIT) plus high-quality surgery (R0 resection with systematic lymphadenectomy >19 nodes) is a promising strategy. However, the value of adjuvant immunotherapy remains unclear. This study aimed to evaluate the as...

Jing-Wei Sun, Pei-Long Bao, Yu-Quan Bai et al. · 0 citations
Open access Sep 2026

Early recurrence patterns after neoadjuvant chemoradiotherapy and chemoimmunotherapy in esophageal squamous cell carcinoma: A multicenter study.

OBJECTIVE To compare early recurrence patterns and survival outcomes between neoadjuvant chemoimmunotherapy (NCIT) and neoadjuvant chemoradiotherapy (NCRT) in patients with locally advanced esophageal squamous cell carcinoma (ESCC). METHODS This retrospective cohort study included 1428 patients with stage IIB-IVA ESC...

Ci-En Sun, Chun-Ji Chen, Hua Sun et al. · 0 citations
Open access Aug 2026

Endogenous CD155 drives metabolic reprogramming via PI3K/AKT/HIF‐1α‐glycolysis axis to mediate anti‐PD‐1 resistance in non‐small cell lung cancer

CD155 is identified as a key driver of anti‐PD‐1 resistance in NSCLC and targeting CD155 combined with anti‐PD‐1 overcomes resistance, supporting a dual‐target therapeutic strategy.

Weiguang Du, Xi-Yang Tang, Yulong Zhou et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.